Starting about 60 years ago, a number of reports appeared that outlined the severe clinical course of a few adult subjects with profound hypogammaglobinemia. Puzzled by the lack of family history and adult onset of symptoms in most, the name "acquired" hypogammaglobinemia was given, but later altered to the current name common variable immune deficiency. Pathology reports remarked on the loss of lymph node architecture and paucity of plasma cells in lymphoid tissues in these subjects.
| INTRODUC TI ON
In 1954, 1 year after the first publication of agammaglobulinemia in a male child, 1 Janeway and Gitlin reported nine additional male children with similar findings and suggested sex-linked inheritance for this immune defect. 2 However, the following year, the first report that agammaglobulinemia was not a disease restricted to either males or children appeared when Sanford et al described a 39 year old agammaglobulinemic woman, who had what we now recognize as common variable immune deficiency (CVID). She had all of the most frequent complications of this disorder, with chronic bronchitis, episodes of bacterial pneumonia, Haemophilus influenzae meningitis, chronic diarrhea, and malabsorption. 3 In the following few years, others recognized similar cases, and commented on the development of severe bronchiectasis leading to respiratory failure, the commonest cause of death. [4] [5] [6] [7] Autopsy reports in these cases showed lymph nodes with poorly defined cortices, no follicle formation and absence of plasma cells in lymph nodes and bone marrow. 7 While it was suggested that plasma cells development was somehow impaired, the significance of this was unclear, as the origin of gamma globulin was not yet established. [6] [7] [8] Some evidence pointed to lack of plasma cell as production of gamma globulin as patients with low serum immunoglobulins did not respond with plasmacytosis in lymph nodes after vaccine antigen stimulation. These observations suggested a connection between loss of these cells and hypogammaglobulinemia, 9 but at this time, the cellular origin of gammaglobulin was still under discussion. Seltzer et al 4 reported that although a hypogammaglobulinemic patient could not be successfully immunized, he still had a positive histoplasmin skin test. This positive test led the authors to propose a lack of correlation between "delayed tissue hypersensitivity and humoral immunity", which was a novel concept at that time. The formal division of cellular and humoral immunity was not demonstrated until a decade later. 10 In contrast to young patients with agammaglobulinemia or hypogammaglobinemia, young adults and older subjects were often diagnosed with "acquired hypogammaglobulinemia". Later efforts to organize the emerging constellation of immune deficiency diseases into a framework by the World Health Organization led to the first consensus statement from a panel of experts. The syndrome of patients with "late onset" immunoglobulin failure was initially identified as variable immune deficiency (common, largely unclassified). Committee has redefined this condition as more of a syndrome, using the term "common variable immunodeficiency disorders", 12 thus retaining the CVID acronym, but emphasizing the intrinsic clinical and genetic heterogeneity.
| CURRENT DEFINITI ON S
Due to the clinical and immunologic heterogeneity, CVID has been variably defined over the years, but according to current consensus, identification should be first based on laboratory criteria:
the immune globulin levels must be lower than the age-adjusted reference range, and for IgG, this is generally <400 mg/dL for adults. Serum IgA (usually) and or IgM must also be low, and vaccine responses to T-dependent and -independent antigens should validate loss of B-cell function. [12] [13] [14] In all cases, other reasons for hypogammaglobulinemia must be carefully excluded, including immune globulin loss, medications, viral infections, known immune defects or other medical reasons for hypogammaglobulinemia. In some respects, the generic term "CVID" is a convenient diagnostic label that can be used to launch appropriate treatment, but it is sometimes, especially for unusual cases, more useful to consider it as a temporary designation, until additional clinical and genetic information emerges. For this reason, CVID definitions have often excluded patients younger than age 4, as in these cases, other genetic causes may indeed be more likely. 12 Although most CVID patients have low to normal numbers of circulating cells with B-cell phenotype, this masks a central failure in the differentiation of B cells into functional immunoglobulin-secreting plasma cells. In fact CVID leads to greatly reduced numbers of isotype-switched CD27 + memory B cells, 15 a characteristic that can now be identified by subpopulation phenotyping in diagnostic panels. 16, 17 Clinical conditions common in CVID, such as infections, autoimmunity, granulomatous infiltrations and lymphoid hyperplasia, have also been included in some current definitions, but due to the heterogeneity of presentation, this has not been easily justified. Gene sequencing is commercially available for many of the known gene defects and are included in primary antibody deficiency panels. While not required for the diagnosis of CVID, molecular dissection can be critically important for treatment optimization and accurate genetic counseling.
| DEMOG R APHIC S
As one of the most common symptomatic primary immunodeficiency, CVID is estimated to affect between 1:25 000 and 1:50 000, with the majority of patients being diagnosed between the ages of 20 and 45; males and females are affected equally. In several series, males tend to be diagnosed earlier. 18, 19 Racial differences are likely and most estimates are based on Caucasian populations; CVID may be less common in patients with African-American ancestry. 20 Due to this well-known heterogeneity, patient cohort and large-scale registry studies have been used over time with benefit, as these develop a more robust picture of disease. [18] [19] [20] [21] [22] [23] [24] While the diagnosis is most typically made in adult life, about 20% of patients are less than 21 years of age at diagnosis, and adult patients often give a history of clinical events suggestive of an immune disorder at an early age. 18, 20, 22 However, in a study of 141 pediatric patients (<21 years of age) evaluated for primary immune deficiency, only four were found to have CVID, suggesting that for some patients, B-cell dysfunction may have evolved over time. 25 In large data collections, most parameters examined in children with pediatric-onset CVID appear quite similar overall to subjects diagnosed in adult life, but some differences were noted. Pediatric-onset CVID patients had more frequent episodes of otitis media, developmental delay, and failure-to-thrive as compared to patients with adult-onset CVID.
Adult CVID patients were more frequently diagnosed with bronchitis, arthritis, depression, and fatigue; they also had somewhat more frequent diagnoses of autoimmunity, lymphoma and other malignancies. 26 In all series, patients in their fifth or later decades have also been reported. The causes of B-cell failure in older adults are unclear, but the most of the genetic defects described below, can also be found in these subjects. In all series, it is apparent that a delay in diagnosis of 6-7 years, after the onset of characteristic symptoms is common in adults, perhaps due to the apparent later onset and phenotypically heterogeneous nature of this disease.
| CLINIC AL S PEC TRUM
The clinical spectrum of CVID is broad but consists of two main phenotypes, predominately recurrent infections that are identified in most subjects, but also autoimmune and/or inflammatory features which may be evident at presentation or after, in approximately 25%-50% of patients. The study of these additional features has been essential. As described in many reports, these inflammatory complications together can be medically challenging, leading to substantial morbidity and/or mortality when compared to patients with infections only. 18, 22 The kinds of infections that develop in CVID and the variety of autoimmune and/or inflammatory complications which occur, are outlined in the following sections.
| Infections
The most common infections, often appearing as the initial symptoms of an immune defect, are upper respiratory tract infections, including pneumonia, chronic bronchitis, and sinusitis. In a Finnish study of 95 patients, sinopulmonary infections were the most common prediagnostic sign or symptom; 66% of patients had suffered from recurrent pneumonia, 60% with recurrent maxillary sinusitis, and 45% with recurrent bronchitis. 24 In the early years, recurrent lung infections leading to bronchiectasis and respiratory failure emerged as the main cause of death in CVID. In one series of 250 patients, 240 had respiratory symptoms, with pneumonia in 147 (61%) of cases. 27 Severe bacterial infections such as meningitis, osteomyelitis and organ abscesses are now uncommon, but still appear in all series of patients. 
| Lung disease
Airway disease is the most common medical problem in CVID, and is often manifest in chronic lower respiratory tract infections leading to bronchiectasis. Curiously, bronchiectasis was not in one study apparently related to serum immunoglobulin levels, suggesting that antibody reconstitution is not the only factor in the development of this complication, but may reflect presence of additional inflammatory conditions. 32 While Ig therapy has significantly reduced the numbers of pneumonias in CVID, 33 To further understand autoimmunity in CVID, B-cell phenotypes have been extensively examined. In subjects with autoimmune cytopenias; the central observation that has emerged is that CD21(low) B cells are substantially increased. 40, 41, 44, 45 In addition, Boileau et al 45 found that T cells in these subjects displayed an activated phenotype 
| Granulomatous disease
Granulomatous disease occurs in 8%-22% of patients with common variable immunodeficiency (CVID). The tissue collections are variable, usually consist of well-formed non-caseating granulomata, and can be found in any organ, although lungs and lymphoid tissues are the most frequent locations. These granulomatous changes, sometimes confused as "sarcoidosis" may be diagnosed on biopsy years prior to the recognition of hypogammaglobulinemia and in such cases, often delays the recognition of the immune defect. 47, 48 Among 436 subjects with CVID in the French Registry, 59 patients (13.5%) were diagnosed with granulomatous disease in one or more organs. This group included 37% males and 63% females. The median age at diagnosis was 40 years but four patients were diagnosed before 18 years of age. Granulomatous disease was diagnosed before or at time of CVID diagnosis in 24 subjects, while in 35 patients; granulomatous disease was diagnosed later, as long as 21 years after the immune defect was recognized. In another study of 455 CVID subjects in the US, 37 patients were known to have granulomatous disease (8.1%). 47 Of these 64.8% were female, 29 were Caucasian, 5 African American, 2 Hispanic, and one was Asian. The median age of patients at time of CVID diagnosis was 29 years. Granuloma were found in many tissues, including lymph nodes, liver, skin, spleen, bone marrow, brain, retinae, small bowel, and kidney. Of these 59%
had moderate to severe respiratory impairment and 54% had one or more episodes of autoimmunity, including ITP, hemolytic anemia, or both. Ten of the 35 subjects for whom current information was known, had died at a median age of 37.5 years. In both cohorts, the association of granuloma, autoimmunity, granulomas, and splenomegaly was noted, as also for other reports. 49, 50 In the French series, there was a suggestion that lymphomas may be more frequent in CVID subjects with granuloma (25% vs. 15%; P = 0.05).
| Enteropathy
Gastrointestinal complaints including bloating, pain and diarrhea, are common in CVID, and linked to both infectious agents as described, are not infrequently told to avoid gluten, and according to a few reports, withdrawal of gluten has appeared to offer benefit. While serologic markers are not useful in dissecting celiac disease in this form of enteropathy, genetic markers may be helpful. 52 However,
for most patients, current consensus is that gluten avoidance is not a useful therapeutic and leads to further weight loss. Jørgensen et al 53 compared the gene expression of small bowel intraepithelial lymphocytes in CVID to samples from celiac subjects, and found non-overlapping features using discriminating pathways analyses. In patients with long-standing enteropathy, an almost graft-vs-host like histology has been reported. Mononuclear cells in these tissues may produce more IL-12 and IFNγ as compared to controls. 54 Innate lymphoid cells (ILC) in these tissues have been identified and may play a role in pathogenesis. 55 A relative lack of plasma cells in the mucosa is common in CVID, and is found more frequently in the colon (56%), followed by rectum (50%), ileum (42%), duodenum (42%), and to a lesser extent in the gastric mucosa (16%). Gastrointestinal plasma cell loss has been correlated with reduced numbers of circulating switched memory B cells and increased numbers of CD21(low) B
cells. Seeking additional markers investigators have reported that
CVID subjects show monocyte and T-cell activation, with increased serum levels of sCD14. 53 In a related study, 16S ribosomal RNAbased profiling of stool samples was used to identify a significant difference in the microbiota of the CVID subjects compared to controls; these alterations could be correlated with increased plasma levels of both LPS and sCD25. 56 
| Liver disease
In early reports of complications stemming from therapeutic management of CVID, viral hepatitis (HBV or HCV) due to infused blood or blood products were noted, but for the past two decades, these have been quite uncommon. Currently, the most common liver pathology is nodular regenerative hyperplasia (NRH). [57] [58] [59] [60] of CVID patients show evidence of liver dysfunction; in many cases, a mildly elevated alkaline phosphatase is observed suggesting liver involvement. This has been consistently reported by numerous investigators. [57] [58] [59] [60] In the absence of clinical reasons for biopsy in most patients, NRH is likely more common than the current estimate of 5% of CVID subjects. 58 NRH may be silent with no clinical consequences and preserved synthetic functions of the liver, but in some cases the pathology leads to cirrhosis, portal hypertension, splenomegaly, esophageal varices, ascites, and jaundice. The cause of NRH, also found in cystic fibrosis, HIV infection, chronic granulomatous disease, and after solid organ transplantation is not known, and treatment is based mostly on lowering portal pressures. Transjugular intrahepatic portosystemic shunts have used, but with unclear success. 61 Liver transplantation has been performed, but the outcome has not been very encouraging overall with recurrent disease in the transplanted liver in some. 62, 63 Other liver conditions noted in some CVID patients are primary biliary cirrhosis and granulomatous disease.
| Neoplastic disease
Individuals with CVID are susceptible to malignancy, and have an estimated 1.8-to 5-fold increased risk of developing cancers of all types. [64] [65] [66] [67] Estimates for lymphoma are higher, possibly 30 times greater than in control populations and in one study, were more common in women. 20, [67] [68] [69] [70] The most frequent malignancy is nonHodgkin lymphoma, although other malignancies such as colorectal, breast, uterine, and neurogenic malignancies have been reported.
In one contemporary report of 473 patients, 39 (8.2%) had a lymphoid malignancy while 33 others (7%), had other cancers, breast, gastric, melanoma, colon, lung, oral, skin, thyroid, vagina, ovary, and esophagus. 18 In contrast to older, published data which suggested a higher incidence of gastric cancer. 23, 71 45 In CVID, these had significantly reduced calcium flux. 77 The first group in this system contains all patients with severe defects of early B-cell differentiation; those with severely reduced switched memory B cells suggesting the presence of a defective germinal center development. 49 Classifying patients into this framework has proven to be useful in gauging the functional capacities of B cells in groups of CVID patients, and has clear clinical relevance. 50, 78 In one study, females with CVID had higher levels 
| IMMUNOLOG IC AB NORMALITIE S

| B-cell immunity
| T-cell defects
In addition to the B-cell defects described above, CVID is often accompanied by substantial global T-cell abnormalities, including reduced T-cell numbers, cytokine defects, and impaired in vitro lymphocyte proliferative response to mitogens and antigens.
Many other T cell defects in CVID have been described, including The T cell repertoire in CVID subjects, as a group, is also both more clonal and less diverse. Ramesh et al noted that the CVID T cell receptor β chain of 44 CVID subjects had significantly less junctional diversity than 22 adult controls, fewer n-nucleotide insertions and deletions, and completely lacked a population of highly modified TCRs seen in controls. The sequences were also significantly more clonal than control DNA, and displayed unique V gene usage.
These abnormalities appeared pervasive, and were also found in outof-frame sequences, and thus would be considered independent of both germinal center selections. Both V region use and clonal expansions, were independent of any specific clinical complications.
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For those CVID subjects with a severe reduction in naive CD4 T cells, the diagnosis of late-onset CID has been suggested, 83 Because "CVID" subjects with very low T cells often have opportunistic infections, some authors have suggested that these subjects should not be included in collections of patients without these features. Indeed, in this study, consanguinity was more common, also suggesting that additional genetic defects are likely to be present. 89 While the origin of the T-cell defects is likely to be intrinsic to the immune defect, an alternative hypothesis for some subjects, at least at diagnosis, might be that chronic translocation of bacterial products could also lead to the relative "exhaustion" of bacterial specific CD4 T cells. In one study, endotoxin was noted in serum in subjects not yet treated with Ig therapy and the CD4 T cells of these subjects revealed proliferative defects, along with higher expression of the programmed death 1 (PD1) receptor. Upon Ig therapy, bacterial translocation resolved and CD4T cell function was restored. 90 
| Cytokine defects
Cytokine defects have long been known in CVID, especially a lack of IL-2 production. These observations led to early clinical trials with this cytokine, which demonstrated some clinical and immunologic benefits. [91] [92] [93] [94] Other cytokine defects or alterations include increased IL-6 95,96 reduced interferon (IFN)-γ, increased TNFα, with low or increased IL-4 [96] [97] [98] In contrast, IL-7, which has a role in the expansion of autoreactive T cell clones, was elevated in a subgroup of CVID patients. 99 Although increased IL-7 levels were not associated with T cell lymphopenia, they were correlated with a more frequent incidence of autoimmunity. ligands. 107, 108 This was suggested as a possible link between pDC defects and B-cell dysfunction, since IFN-α is known to augment both TLR-induced B-cell activation and maturation. 109 In fact, in one study, exogenous IFN-α could partially rescue the defective TLR7-induced class switching in CVID B cells.
107,108
In a recent study, a CD127(+), CD161(+) lymphoid population containing T-box transcription factor, retinoic acid-related orphan receptor (ROR) γt, IFN-γ, IL-17A, and IL-22, were found expanded in the peripheral blood of patients with CVID with inflammatory conditions. In these, a mean of 3.7% of PBMCs were in this category. With the phenotype identified, these cells had the hallmarks of type 3 ILC3, and an inflammatory potential. The same cells were also found in gastrointestinal and lung biopsy tissues of CVID suggesting a role in this mucosal inflammation. 55 A second study identified a similar ILC3 expansion, but also showed a relative loss of ILC2 cells, especially for those subjects with enteropathy. 110 
| MORB IDIT Y AND MORTALIT Y
Using a large data set of 2134 CVID patients compiled by the ESID Registry from 28 medical centers, risk of overall morbidity and mortality has been examined. In this cohort, 119 (7.4%) of patients were deceased. Older age at onset of symptoms, older age at diagnosis, and diagnostic delay were all associated with an increased risk of death (P < .001). While lymphoma or solid tumor was associated with an increased risk of death, no other clinical complications were found associated. 19 This is in contrast to a previous study using a curated ESID data for a CVID cohort, in which subjects with noninfections complications had a clearly reduced survival. 22 This study was also validated in a single center study in the USA, in which demographic and immunologic markers associated with complications and poorer survival were investigated in another large cohort. 18 Here, the median age at death was 44 years for females and 42 years for males, both significantly different from age-matched population controls. The overall mortality in the US cohort over a 4-decade interval was 19.6%. Notably, both the ESID and US data show that significant improvement in mortality has occurred over time, as com- (HR = 1.005; P = 0.0021) were all associated with increased mortality in this study. 18 Separately, mortality in CVID subjects with granulomatous disease has been examined. In one study, there was a median survival of 13.7 years in CVID patients with granulomatous/ lymphoid interstitial infiltrates, as compared to 28.8 years in those without this complication. 34 Finally, in contrast to both the US and ESID studies, CVID mortality in Iran showed quite different characteristics. In a study of this population, CVID mortality was 0.42 per 100 000, but with the highest rate for children of ages 5-14. In these cases, the highest mortality was noted in subjects with infections, while the second highest mortality was found for subjects with polyclonal lymphocytic infiltrations. 112 These authors pointed out the need for earlier recognition and treatment of the immune defect.
| G ENE TI C DEFEC TS LE AD ING TO THE C VID PHENOT YPE
Because of the late onset of clinical symptoms and striking heterogeneity, for most of its history, CVID has been assumed to be a polygenic syndrome. However, the possibility that the immune de- 
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In a number of studies in the past two decades, linkage studies, whole exome and whole genome analyses have revealed monogenic causes that lead to the CVID phenotype. The first of these were autosomal recessive genes, but an increasing number of autosomal dominant genes with variable penetrance have now been documented. While overall, these may underlie the syndrome in perhaps 10% of subjects, in families and selected patient groups, a monogenic cause has been assigned to as many as 30% of subjects. [114] [115] [116] As one might suspect, the genes identified reflect the complex requirements of B-cell antigen signaling, activation, survival, migration, and maturation to the plasma cell stage. As it is now apparent, defects in many receptors, activators and co-stimulators, can lead to either moderate or profound B-cell impairment, and ultimately, hypogammaglobinemia. In these cases, the diagnosis of CVID has often been applied. An additional emerging theme in the study of human B-cell defects is that mutations in genes involved in immune regulation in general, are also likely to lead to the initial clinical phenotype of antibody deficiency, with hypogammaglobulinemia being an early and cardinal feature. The genetic defects identified in subjects with the CVID phenotype, are outlined on Table 1 . The main genes linked to this syndrome, are discussed below.
| ICOS deficiency
Autosomal recessive mutations in the gene encoding the inducible Tcell costimulator (ICOS), a T-cell surface receptor, was one of the first genetic causes of CVID to be identified. 117 ICOS, a member of the CD28 and CTLA4 (cytotoxic T lymphocyte associated protein 4) family of proteins is required for interaction with its cognate receptor on antigen presenting cells (B7) and is required for germinal center formation and terminal B-cell differentiation. Activated CD3(+)CD4(+)
T lymphocytes in one kindred with a frameshift deletion, demonstrated a complete absence of ICOS expression and a reduction in circulating T follicular helper cells. 118 Patients with homozygous and compound heterozygous mutations have been reported and have a variable age of onset. The severity of this rare immune defect is quite diverse, and may include inflammatory bowel disease, abnormal liver enzymes, enteropathy and/or opportunistic infections. 
| BAFF receptor deficiency
| Interferon regulatory factor-2 binding protein 2 (IRF2BP2)
A heterozygous missense mutation was found in a father and his two children who were diagnosed with CVID. In vitro studies showed that stimulation of the proband's lymphocytes demonstrated impaired formation of B-cell plasmablasts. 
| Major histocompatibility genes and MSH5
For many years, it has been noted that there may be subjects with
IgA deficiency or CVID in the same family; furthermore, selective IgA deficiency may in rare cases, evolve into CVID. These genetic studies suggested a common pathogenic basis for these common antibody defects; further analyses suggested a possible linkage to the MHC region, in particular, associated haplotypes HLA (HLA) A1-B8-DR3
and B14-DR1. 137, 138 Several single nucleotide polymorphisms in the gene encoding MSH5, a DNA mismatch repair protein with likely involvement in class switch recognition, was reported to occur more frequently in CVID and IgA deficiency in a combined study of U.S.
and Swedish patients. 139 However, these polymorphisms are also found in healthy individuals, thus its role in CVID is unclear. enteropathy and granulomatous infiltrative lung disease. [144] [145] [146] As an autosomal defect with variable penetrance, an estimated 67% of relatives with the same mutations were clinically affected. 147 In selected cases, the loss of CTLA-4 can be treated with a CTLA4 fusion drug, abatacept. 
| Deficiency in genes linked
| Nuclear factor kappa-B
In addition to the above, mutations in transcription factors of the nuclear factor kappa-B (NF-κB) family are now being described in increasing numbers of subjects with "CVID"; in fact, defects in the NFKB1 subunit appear to be the most common genetic defect in CVID subjects of Caucasian background. 114, 154 These also lead to a quite variable form of autosomal dominant antibody deficiency, with respiratory infections, unusual infections, autoimmunity and lymphoproliferative disease. 115, 154, 155 First reported in a large Dutch family with six subjects with CVID in three generations, the family was re-investigated and additional members were found to have moderate to severe hypogammaglobulinemia or IgA deficiency. 156, 157 Subsequently in this and two other families, different heterozygous mutations in the NFKB1 gene were identified. 158 As for other autosomal dominant defects described above, not all subjects with mutations in the same family were affected, demonstrating the variable penetrance of defects in these genes.
In addition to the NFKB1 gene, autosomal dominant, heterozygous mutations in NFΚB2 may also lead to early onset hypogammaglobulinemia with recurrent infections. Autoimmunity, alopecia in some, but more commonly, endocrine abnormities adrenocorticotropic hormone insufficiency or other pituitary hormone deficiencies were found. 159 The first to be described were in the C-terminal region of NFKB2, leading to disruption of p100 phosphorylation, inhibition of processing into the p52 active form, and prevention of nuclear translocation.
Additional nonsense gain-of-function mutations have been identified in other patients, resulting in constitutive NF-κB2 activation; these patients had a complex immune disorder with hypogammaglobulinemia, lymphopenia, and more severe T-cell defects. 164 and ATPase H+ transporting accessory protein 1 (ATP6AP1) deficiency 165 and phospholipase C, gamma-2 (PLCG2). 166 
| TRE ATMENT
The standard of care in CVID treatment is replacement immune globulin (Ig) given at frequent intervals for life, via the i.v. or subcutaneous route. 167 Ig greatly reduces the number of bacterial infections 168 and data collected over the past 30 years demonstrates that this increases life expectancy. Antibiotics are also needed for acute treatment, and many cases, are used on a chronic basis as prophylaxis. However, Ig does not appear to protect against or treat the non-infectious inflammatory complications such as functional and structural lung disease, autoimmunity, granulomatous disease, or the development of cancer or lymphoma as discussed above. 18, 22 The autoimmune and inflammatory complications are commonly difficult to treat. While autoimmune cytopenias such as immune thrombocytopenia and hemolytic anemia, may respond to high dose immunoglobulin and/or steroids, added therapy such as rituximab has been widely used, and often provides long term benefit. 169 In one retrospective multicenter study, rituximab was highly effective 33 patients with CVID-associated immune cytopenias, leading to an initial response rate of 80 % and a sustained response rate of 50%, after a mean follow up of 39 ± 30 months following the first administration. Other more recent options for cytopenias include thrombopoietin-receptor agonists, which have also shown benefit. 170 However, in some cases splenectomy has already been performed, usually for treatment of cytopenias, but also for an increasingly large spleen and/or concern for lymphoma. While rituximab has largely supplanted splenectomy for resolution of cytopenias in many patients, it has often been performed before the diagnosis of CVID. However, review of large data sets has shown that a previous splenectomy did not increase mortality in CVID as long as adequate immunoglobulin replacement therapy was used. 18, 163 Therefore this treatment is likely protect against postsplenectomy infections.
18,171
The management of inflammatory bowel disease in CVID is similar as for immunocompetent patients, including antibiotics, such as metronidazole or tinidizole or ciprofloxacin, 5-aminosalicylic acid and/or non-absorbed oral steroids such as budesonide, but these therapies seem less successful in CVID. Low-dose corticosteroids such as prednisone can be used in low doses of 10 mg/d; however, higher doses can lead to a significant risk of infections.
Immunomodulators, such as azathioprine or 6-mercaptopurine, can be used and do not appear to affect standard T-and B-cell function tests. 172 Biologics such as infliximab and ustekinumab (anti-IL-12 and IL-23) or more recently, vedolizumab have been used in few cases with some benefit in severe enteropathy. Azathioprine, cyclosporine, mycophenolate mofetil, sirolimus, infliximab, and thalidomide, which led to partial or no response. 48 Mullighan reported granuloma in 20 of 90 patients with CVID (22%); eight of these had an unusual TNF-alpha allele (TNF +488A), 98 but TNF-alpha production or levels were not examined. However, as previous work suggested that some CVID patients had elevated serum levels of TNF-alpha, 174 TNF-alpha inhibitors (infliximab or etanercept) have been used in subjects with CVID with granuloma, with benefit in some cases [175] [176] [177] ; however, no controlled trials have been performed. More recently, taking into account the lymphoid infiltrations that accompany the granulomatous involvement, the use of combination therapy with rituximab along with either azathioprine, 6MP or mycophenolate mofetil, has become more commonly accepted measures, especially in those with granulomatous lung disease. 178 The discovery that mutations in regulatory genes can lead to both B-cell dysfunction and the clinical complications characteristic of CVID, has led to important insights into more directed therapy. As noted above, the use of CTLA4 fusion protein, abatacept, to correct for loss of CTLA4, is a striking example. 148 In addition, chloroquine long known a lysosomal inhibitor, was noted to protect against loss of CTLA-4 in LRBA-deficient cells, thus its use could have a therapeutic role in this disease. 179 This drug has been used for many decades for rheumatologic illnesses with a known safety record.
For patients with mutations in PIK3CD or PIK3R1, hyperactivation of PI3K leads to unrestrained immune activation by generation of PI(3,4,5)P3 signals and activation of protein kinase B, also known as AKT. The result is activation of downstream pathways including the mammalian target of rapamycin kinase. With this in mind the logical drug, rapamycin has been used to retrain this pathway. Even more specific, is the p110δ-specific inhibitor, Idelalisib, already in used in chronic lymphocytic leukemia. 179 With the evolving understanding that the CVID syndrome with the additional cellular defects lead to poorer survival for some, hematopoietic stem cell transplant (HSCT) has been performed.
While data on the long-term effects for subjects with clearly defined CVID are still limited, a recent multi-center study reported improved outcome for some, but poor outcome for many. In this study 25 CVID patients aged 8-50 years, often with immune dysregulation had an overall survival of 48%, and 83% for those with lymphoma. The major causes of death were treatment-refractory graft-versus-host disease, poor immune reconstitution and infectious complications. For the surviving and reconstituted subjects,
Immunoglobulin substitution was stopped in 50%; for 92% of the surviving patients, the condition for which HSCT has been performed, resolved. 
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